[1] |
Ostrom QT, Cioffi G, Waite K, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018[J]. Neuro Oncol, 2021, 23(12 Suppl 2): iii1-iii105.
|
[2] |
Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6): 1351-1359.
pmid: 4983156
|
[3] |
Thomas A, Noël G. Medulloblastoma: optimizing care with a multidisciplinary approach[J]. J Multidiscip Healthc, 2019, 12: 335-347.
doi: 10.2147/JMDH.S167808
pmid: 31118657
|
[4] |
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251.
doi: 10.1093/neuonc/noab106
|
[5] |
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2): 97-109.
doi: 10.1007/s00401-007-0243-4
|
[6] |
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.
doi: 10.1007/s00401-016-1545-1
|
[7] |
Carvalho RM, Pinto GR, Yoshioka FK, et al. Prognostic value of the TP53 Arg72Pro single-nucleotide poly-morphism and susceptibility to medulloblastoma in a cohort of Brazilian patients[J]. J Neurooncol, 2012, 110(1): 49-57.
doi: 10.1007/s11060-012-0950-0
|
[8] |
de Haas T, Hasselt N, Troost D, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression[J]. Clin Cancer Res, 2008, 14(13): 4154-4160.
doi: 10.1158/1078-0432.CCR-07-4159
|
[9] |
Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)[J]. J Clin Oncol, 2021, 39(7): 822-835.
doi: 10.1200/JCO.20.01372
pmid: 33405951
|
[10] |
Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis[J]. Lancet Oncol, 2016, 17(4): 484-495.
doi: S1470-2045(15)00581-1
pmid: 26976201
|
[11] |
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization[J]. Clin Cancer Res, 2004, 10(21): 7252-7259.
doi: 10.1158/1078-0432.CCR-04-0713
|
[12] |
Akaike H. A new look at the statistical model identification[M/OL]. Selected Papers of Hirotugu Akaike. Springer Series in Statistics. Springer, New York, NY. http://doi.org/10.1007/12-1694-0_16.
|
[13] |
Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators[J]. Eur Urol, 2018, 74(6): 796-804.
doi: S0302-2838(18)30640-7
pmid: 30241973
|
[14] |
Huybrechts S, Le Teuff G, Tauziède-Espariat A, et al. Prognostic clinical and biologic features for overall survival after relapse in childhood medulloblastoma[J]. Cancers (Basel), 2020, 13(1): 53.
doi: 10.3390/cancers13010053
|
[15] |
Hill RM, Richardson S, Schwalbe EC, et al. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study[J]. Lancet Child Adolescent Health, 2020, 4(12): 865-874.
doi: 10.1016/S2352-4642(20)30246-7
|
[16] |
Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study[J]. J Clin Oncol, 1999, 17(3): 832-845.
pmid: 10071274
|
[17] |
Kortmann RD, Kühl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91[J]. Int J Radiat Oncol Biol Phys, 2000, 46(2): 269-279.
doi: 10.1016/S0360-3016(99)00369-7
|
[18] |
Taylor RE, Bailey CC, Robinson KJ, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy[J]. Eur J Cancer, 2005, 41(5): 727-734.
pmid: 15763649
|
[19] |
Lee JW, Lim DH, Sung KW, et al. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma[J]. Cancer Med, 2020, 9(16): 5807-5818.
doi: 10.1002/cam4.3199
|
[20] |
Dietzsch S, Placzek F, Pietschmann K, et al. Evaluation of prognostic factors and role of participation in a randomized trial or a prospective registry in pediatric and adolescent nonmetastatic medulloblastoma - a report from the HIT 2000 trial[J]. Adv Radiat Oncol, 2020, 5(6): 1158-1169.
|
[21] |
Dhall G, O'Neil SH, Ji L, et al. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial[J]. Neuro Oncol, 2020, 22(12): 1862-1872.
doi: 10.1093/neuonc/noaa102
|
[22] |
AL-Afif S, Krauss JK, Helms F, et al. Long-term impairment of social behavior, vocalizations and motor activity induced by bilateral lesions of the fastigial nucleus in juvenile rats[J]. Brain Struct Funct, 2019, 224(5): 1739-1751.
doi: 10.1007/s00429-019-01871-3
|
[23] |
Hoche F, Guell X, Vangel MG, et al. The cerebellar cognitive affective/Schmahmann syndrome scale[J]. Brain, 2018, 141(1): 248-270.
doi: 10.1093/brain/awx317
|
[24] |
Lanier JC, Abrams AN. Posterior fossa syndrome: review of the behavioral and emotional aspects in pediatric cancer patients[J]. Cancer, 2017, 123(4): 551-559.
doi: 10.1002/cncr.30238
pmid: 27787875
|
[25] |
von Hoff K, Hartmann W, von Bueren AO, et al. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors[J]. Pediatr Blood Cancer, 2010, 54(3): 369-376.
doi: 10.1002/pbc.22339
|
[26] |
Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma[J]. Acta Neuropathol, 2012, 123(4): 501-513.
doi: 10.1007/s00401-011-0923-y
|
[27] |
Srivastava VK, Nalbantoglu J. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics[J]. Cancer Biol Ther, 2010, 9(11): 843-852.
pmid: 20372085
|
[28] |
Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma[J]. Clin Cancer Res, 2004, 10(22): 7613-7620.
doi: 10.1158/1078-0432.CCR-04-0499
|
[29] |
Korshunov A, Savostikova M, Ozerov S. Immuno-histochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression[J]. J Neurooncol, 2002, 58(3): 271-279.
doi: 10.1023/A:1016226319068
|